Biotech · Private company · Brooklyn, NY, US
Jillion Therapeutics Inc.
Track this companyFree. Adds Jillion Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards5
- Advancing DEL-derived Small Molecule Inhibitors of Pathological Tau Toward Preclinical Development for Alzheimer’s Disease and TauopathiesFiscal year 2026 · $1.1MNIH RePORTER 2R44AG085856-02 · fetched Nov 12, 2026
- Identification of therapeutic molecules to treat amphetamine use disorders using our DNA-encoded library (DEL) technologyFiscal year 2025 · $398.1KNIH RePORTER 1R43DA061909-01 · fetched Nov 12, 2026
- Synergy between Artificial Intelligence and DNA-Encoded Library technologies to Identify Polypharmacological Therapeutics for Substance Use DisordersFiscal year 2025 · $399.5KNIH RePORTER 1R43DA062975-01 · fetched Nov 12, 2026
- Targeting biologically relevant tau monomers and oligomers using a novel DEL drug discovery platform to treat Alzheimer’s disease and tauopathiesFiscal year 2024 · $496.4KNIH RePORTER 1R43AG085856-01A1 · fetched Nov 12, 2026
- The use of DNA-encoded library (DEL) technology for the identification of therapeutic molecules to treat opioid use disorders (OUDs)Fiscal year 2024 · $399.9KNIH RePORTER 1R43DA061688-01 · fetched Nov 12, 2026